[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tam Anh Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,61,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100565141","hepatitis-delta-virus-infection-cross-sectional-study-in-patients-with-chronic-hepatitis-b-virus-infection-100565141",false,"NCT06638320","Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 16 years old undergo testing at the Testing Center of Tam Anh General Hospital or Tam Anh TP. Ho Chi Minh General Hospital, with chronic hepatitis B HBsAg (+) standards for six months or over or HBsAg (+) combined with HBcAb total (+) and HBcAb-immunoglobulin M (-).\n* Patients ≥ 16 years old with chronic hepatitis B come to be examined or are inpatients at the Gastroenterology - Hepatobiliary Center of Bach Mai Hospital, diagnosed with hepatocellular carcinoma, and cirrhosis\n\nExclusion Criteria:\n\n* Patients do not agree to participate in the study or refuse to sign a written informed consent.","ALL","16 Years",{"count":18,"type":19},2452,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the prevalence of hepatitis D virus (HDV) and the distribution of the HDV genotype in patients with chronic hepatitis B infection. It will also identify factors related to hepatitis D virus infection, such as characteristics of the study sample, vaccination history, drug use affecting hepatitis, family factors, environment, and lifestyle.\n\nThis study will be conducted at Tam Anh General Hospital, Bach Mai Hospital and Tam Anh TP. Ho Chi Minh General Hospital.\n\nParticipants will be interviewed directly through a questionnaire to collect some information related to epidemiological risk factors. A blood sample will also be collected.",[23,24],"Hepatitis Delta With Hepatitis B Carrier State","Chronic Hepatitis b","RECRUITING","2026-06-17",{"date":28,"type":29},"2026-06-22","ACTUAL",{"date":31,"type":29},"2024-11-01",{"date":33,"type":19},"2026-12-30",{"name":35,"class":36},"Tam Anh Research Institute","OTHER",3,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":37},"100642897","epidemiological-characteristics-and-clinical-burden-of-rsv-infection-in-children-under-24-months-in-ho-chi-minh-city-2026-2028-100642897","NCT07640581","Epidemiological Characteristics and Clinical Burden of RSV Infection in Children Under 24 Months in Ho Chi Minh City (2026-2028)","Assessing the Epidemiological Characteristics and Clinical Burden of Respiratory Syncytial Virus (RSV) Infection in Children Aged 0-24 Months in Primary Healthcare Settings of Ho Chi Minh City, Vietnam (2026 - 2028)","RSV pediatric","Inclusion Criteria:\n\n* Children aged 0 to \\\u003C24 months (i.e., less than two years old).\n* Children presenting with a diagnosis of acute respiratory infection (ARI), defined as an illness with one or more of the following symptoms: cough, rhinorrhea, sore throat, dyspnea (including wheezing, tachypnea, or apnea\u002Fincreased work of breathing), sepsis (for infants aged \\\u003C6 months), and\u002For fever.\n* Children residing in the lowest administrative division (Phường \u002F Xã) in Vietnam that is designated for the specific study site (outpatient clinic or community hospital). As patients live in the same administrative district as the healthcare facility, this will facilitate follow-up and ensure that the study results are representative of the range of severity of ARI presenting to each specific study site.\n* Parent or LAR provides written informed consent for their child's participation.\n\nExclusion Criteria:\n\n* Children whose mothers received a maternal RSV vaccine during pregnancy or who have themselves received RSV-specific monoclonal antibodies (mAbs).\n* Children with a known non-respiratory cause for hospitalization.\n* Children with respiratory symptoms lasting over 14 days.\n* Children hospitalized elsewhere within the preceding 4 days, excluding admission to the Emergency Department.\n* Children already enrolled in another RSV study within the preceding 3 months.","0 Months","24 Months",{"count":49,"type":19},2000,"This is a prospective, observational, multicenter study employing continuous, convenience sampling, stratified by study site and by fortnightly interval, enrolling until the target sample sizes are achieved over the first epidemiological season (2026) and the second epidemiological season (2027). The study population includes children aged 0 to 24 months presenting to the outpatient or inpatient facilities of the study sites with signs and symptoms of acute respiratory infection (ARI). In Vietnam there is no single guideline for diagnosing ARI, but rather there are guidelines specific to clinical conditions such as pharyngitis, rhinitis, tonsilitis, or pneumonia. This study will use an operational definition where ARI is defined as the presence of one or more of the following clinical features: cough, rhinorrhea, sore throat, dyspnea, and \u002F or fever.\n\nRSV testing using nasopharyngeal (NP) swabs will be collected from all eligible children with consent to participate in the study; if a NP swab is not feasible, a mid-turbinate nasal swab will be used. Specimens will be transported to a central laboratory for real-time, reverse transcription-polymerase chain reaction (RT-PCR) testing.\n\nFurthermore, the stored viral transport media from all the RSV-positive samples will be used for whole genome sequencing (WGS) to determine the subgroup (A or B) of the circulating RSV strains and to analyze the genotype.\n\nThe parent or legally acceptable representative (LAR) of pediatric patients will provide information regarding the patient's demography, such as the family's socioeconomic status and household environment (e.g., exposure to tobacco smoke, overcrowding). The children's immunization history and their mothers' immunization history (i.e., vaccines such as influenza and Tdap received during the pregnancy as part of a maternal immunization program) will be established, which is not to estimate vaccine effectiveness but to document the level of vaccine uptake in these populations during the study. Children with maternal RSV vaccination will be excluded.\n\nCrucially, the parent or LAR also will report on the child's complete medical history, including perinatal \u002F pregnancy history, presence of congenital anomaly, previous history of illness, and detailed history and clinical course of the current illness episode. Maternal hypertension and history of immunological factors will not be explored. Data on the medical treatment will be abstracted from the patients' medical records.\n\nOne month after the outpatient clinic visit or hospital discharge, the parent or LAR will be contacted via mobile phone to ascertain the children's current health status and to collect information on the family's direct costs due to the illness.",[52],"Acute Respiratory Infections (ARIs)","2026-06-06",{"date":55,"type":29},"2026-06-10",{"date":57,"type":29},"2026-06-04",{"date":59,"type":19},"2028-08-01",{"name":35,"class":36},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":15,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100611353","dexdes-trial-dexmedetomidine-desflurane-combination-in-laparoscopic-colectomy-100611353","NCT07239479","DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy","Efficacy and Safety of Dexmedetomidine Combined With Desflurane in Laparoscopic Colectomy: A Randomized Double-Blind Controlled Clinical Trial (DEXDES Trial)","Inclusion Criteria:\n\n* Age 18-65 years\n* ASA Physical Status I-II\n* Elective laparoscopic colectomy\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, or renal disease\n* COPD or bronchial asthma\n* Chronic opioid or psychotropic medication use\n* Atrioventricular block (grade II-III), sick sinus syndrome\n* Significant intraoperative bleeding or hemodynamic instability","18 Years","65 Years",{"count":71,"type":19},40,"INTERVENTIONAL",[74],"NA","This randomized double-blind controlled clinical trial aims to evaluate the efficacy and safety of combining Dexmedetomidine with Desflurane in patients undergoing elective laparoscopic colectomy. The study will assess whether the combination can reduce Desflurane consumption, improve intraoperative hemodynamic stability, and enhance postoperative recovery compared to Desflurane alone.",[77],"Colorectal Neoplasms",[79,80,81,82,83,84],"Dexmedetomidine","Desflurane","General anesthesia","Colorectal surgery","ERAS","Hemodynamic stability","2025-12-28",{"date":87,"type":29},"2025-12-30",{"date":89,"type":29},"2025-12-01",{"date":91,"type":19},"2027-01-30",{"name":35,"class":36},1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":93},"100611361","genotype-and-disease-burden-of-rsv-in-older-vietnamese-adults-rsv-respiratory-syncytial-virus--100611361","NCT07239583","Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )","A Description of the Proportion, Genotype Distribution of Respiratory Syncytial Virus and the Severity of Disease in Hospitalized Elderly in Vietnam","RSV-VN-Elderly","Inclusion Criteria:\n\nTo be enrolled in the study, participants must meet all inclusion criteria:\n\n1. Individuals ≥ 60 years old at the time of screening (calculated from the date of birth to the date of screening)\n2. ARI or exacerbation of cardiopulmonary diseases diagnosed at the time of admission. ARI or ARI-compatible symptoms were defined as either:\n\n   * New onset or increase from baseline of: nasal congestion, rhinorrhea, sore throat, hoarseness, cough, sputum production, dyspnea, wheezing, hypoxemia, or\n   * Admitting diagnosis suggestive of ARI (e.g., pneumonia, upper respiratory infection, bronchitis, influenza, cough, viral respiratory illness, respiratory distress, or respiratory failure), or\n   * Admitting diagnosis was the exacerbation of an underlying cardiac or pulmonary disease involving acute respiratory symptoms within the previous 2 weeks (e.g., congestive heart failure \\[CHF\\], chronic obstructive pulmonary disease \\[COPD\\], or asthma exacerbation).\n3. The participant agrees to voluntarily participate in this study.\n\nExclusion Criteria:\n\nTo be enrolled in the study, participants must have none of the exclusion criteria:\n\n1. Symptom onset \\> 6 days prior to screening date\n2. Acute symptoms confirmed to be unrelated to infection or as assessed by the investigator\n3. Admission to any hospital within the 30 days preceding the screening date\n4. Previously enrolled in the study in the last 45 days","60 Years",{"count":104,"type":19},1000,"This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease.",[107,108],"Respiratory Syncytial Virus Infection","Respiratory Syncytial Virus Infections",[110,111,112,113,114,115],"Respiratory Syncytial Virus (RSV)","Acute Respiratory Infection (ARI)","Metagenomic Sequencing (mNGS)","RSV Genotype","Disease Severity","Healthcare Resource Utilization","2025-11-16",{"date":118,"type":29},"2025-11-20",{"date":120,"type":29},"2025-10-06",{"date":122,"type":19},"2027-03-30",{"name":35,"class":36},""]